An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Applied Biochemistry and Biotechnology

• Publication date

  2023-10-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12010-023-04748-8PMID 37897621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage

  2021cited by this paper
• KRAS G12C Mutations in NSCLC: From Target to Resistance

  2021cited by this paper
• Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling

  2021cited by this paper
• Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

  2020cited by this paper
• Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)

  2020cited by this paper
• Current therapy of KRAS-mutant lung cancer

  2020influential reference
• The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.

  2020influential reference
• microRNA-1298 inhibits the malignant behaviors of breast cancer cells via targeting ADAM9

  2020cited by this paper
• Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

  2019cited by this paper
• FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

  2019cited by this paper
• Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

  2019cited by this paper
• KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer

  2019cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• De novo lipogenesis represents a therapeutic target in mutant Kras non‐small cell lung cancer

  2018cited by this paper
• Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

  2017cited by this paper
• Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

  2017cited by this paper
• Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.

  2017cited by this paper
• Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

  2017cited by this paper
• Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

  2017influential reference
• The immune contexture in cancer prognosis and treatment

  2017cited by this paper
• Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer

  2016cited by this paper
• The multifaceted roles of fatty acid synthesis in cancer

  2016cited by this paper
• Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

  2015cited by this paper
• FAK to the rescue: activated stroma promotes a "safe haven" for BRAF-mutant melanoma cells by inducing FAK signaling.

  2015cited by this paper
• FAK in cancer: mechanistic findings and clinical applications

  2014cited by this paper
• PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

  2014cited by this paper
• A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer

  2014cited by this paper
• Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

  2014influential reference
• Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.

  2014cited by this paper
• Heat shock protein 90 inhibitors in non-small-cell lung cancer

  2014influential reference
• KRAS mutations in lung cancer.

  2013cited by this paper
• RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

  2013cited by this paper
• The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor

  2013cited by this paper
• Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

  2013influential reference
• Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

  2013cited by this paper
• The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  2013cited by this paper
• Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

  2013cited by this paper
• Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

  2013cited by this paper
• Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.

  2013cited by this paper
• A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).

  2013cited by this paper
• Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

  2012cited by this paper
• Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

  2012cited by this paper
• Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.

  2012cited by this paper
• Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

  2012cited by this paper
• A comprehensive survey of Ras mutations in cancer.

  2012cited by this paper
• Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas

  2012cited by this paper
• PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

  2011cited by this paper
• The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.

  2011cited by this paper
• RAS oncogenes: weaving a tumorigenic web

  2011cited by this paper
• Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

  2011cited by this paper
• Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.

  2010cited by this paper
• Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.

  2010cited by this paper
• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  2010cited by this paper
• Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

  2010influential reference
• Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis*

  2010cited by this paper
• Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

  2009cited by this paper
• Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

  2009cited by this paper
• Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

  2009influential reference
• KRAS mutations in non-small cell lung cancer.

  2009cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.

  2008influential reference
• Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.

  2008cited by this paper
• Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

  2008cited by this paper
• Non-small Cell Lung Cancer Treatment

  2007cited by this paper
• Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

  2006cited by this paper
• V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.

  2006cited by this paper
• Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

  2006cited by this paper
• RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival

  2006cited by this paper
• Molecular Context of the EGFR Mutations: Evidence for the Activation of mTOR/S6K Signaling

  2006cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.

  2005cited by this paper
• PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.

  2005cited by this paper
• Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers

  2002cited by this paper
• Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

  2002influential reference
• Hsp90 as a capacitor for morphological evolution

  1998cited by this paper
• Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase

  1995cited by this paper

• Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma.

  2025cites this paper
• KRAS突变型非小细胞肺癌的免疫治疗进展

  2025cites this paper
• Mycoremediation of heavy metals by Curvularia lunata from Buckingham Canal, Neelankarai, Chennai

  2024cites this paper